Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome

Clinical Cancer Research

Volumn 16, Issue 13, 2010, Pages 3356-3367

  Jönsson, Göran ^a   Busch, Christian ^b   Knappskog, Stian ^b   Geisler, Jürgen ^b,c,d   Miletic, Hrvoje ^b,c   Ringnér, Markus ^a   Lillehaug, Johan R ^b   Borg, Åke ^a   Lønning, Per Eystein ^b,c  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DACARBAZINE; DNA;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; EPIGENETICS; FEMALE; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENOME; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; SYSTEMIC THERAPY; TAXONOMY; TUMOR IMMUNITY; VALIDATION STUDY; WILD TYPE;

DNA COPY NUMBER VARIATIONS; GENE DELETION; GENE EXPRESSION PROFILING; GENES, P16; HUMANS; MELANOMA; MUTATION; NEOPLASM METASTASIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; VALIDATION STUDIES AS TOPIC;

EID: 77954234849     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2509     Document Type: Article

References (30)

1. Purdue MP, Freeman LE, Anderson WF, Tucker MA. Recent trends in incidence of cutaneous melanoma among U.S. Caucasian young adults. J Invest Dermatol 2008;128:2905-8.
2. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:998-1012.
3. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
4. Lorigan P, Eisen T, Hauschild A. Systemic therapy for metastatic malignant melanoma-from deeply disappointing to bright future? Exp Dermatol 2008;17:383-94.
5. High WA, Stewart D, Wilbers CR, Cockerell CJ, Hoang MP, Fitzpatrick JE. Completely regressed primary cutaneous malignant melanoma with nodal and/or visceral metastases: a report of 5 cases and assessment of the literature and diagnostic criteria. J Am Acad Dermatol 2005;53:89-100. (Pubitemid 40826701)
6. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000;406:536-40.
7. Mandruzzato S, Callegaro A, Turcatel G, et al. A gene expression signature associated with survival in metastatic melanoma. J Translatl Med 2006;4:50.
8. Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 2006;98:472-82.
9. Bogunovic D, O'Neill DW, Belitskaya-Levy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A 2009;106: 20429-34.
10. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47.
11. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. BioTechniques 2003; 34:374-8.
12. Jonsson G, Staaf J, Olsson E, et al. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2007;46: 543-58.
13. Staaf J, Jonsson G, Ringner M, Vallon-Christersson J. Normalization of array-CGH data: influence of copy number imbalances. BMC Genomics 2007;8:382.
14. Autio R, Hautaniemi S, Kauraniemi P, et al. CGH-Plotter: MATLAB toolbox for CGH-data analysis. Bioinformatics (Oxford, England) 2003;19:1714-5.
15. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-41.
16. Elder DE, Guerry Dt, VanHorn M, et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm). Cancer 1985;56:413-8. (Pubitemid 15031668)
17. Clark WH, Jr., Elder DE, Guerry Dt, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-904.
18. Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 2005;102: 6092-7.
19. John T, Black MA, Toro TT, et al. Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res 2008;14: 5173-80.
20. Johansson P, Pavey S, Hayward N. Confirmation of a BRAF mutation-associated gene expression signature in melanoma. Pigment Cell Res 2007;20:216-21. (Pubitemid 46776377)
21. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A, Peterson C. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol 2002;3, SOFTWARE0003.
22. Fredlund E, Ringner M, Maris JM, Pahlman S. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci U S A 2008;105:14094-9.
23. Liu Z, Maas K, Aune TM. Identification of gene expression signatures in autoimmune disease without the influence of familial resemblance. Hum Mol Genet 2006;15:501-9.
24. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
25. Edlundh-Rose E, Egyhazi S, Omholt K, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006;16:471-8.
26. Jonsson G, Dahl C, Staaf J, et al. Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene 2007;26: 4738-48.
27. Conway C, Mitra A, Jewell R, et al. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 2009;15:6939-46.
28. Pavey S, Johansson P, Packer L, et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 2004;23:4060-7.
29. Freedberg DE, Rigas SH, Russak J, et al. Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst 2008; 100:784-95.
30. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-22.